BRC Q4 Sales $1.80M Miss $68.90M Estimate

BRC (NYSE:BRCC) reported quarterly sales of $1.80 million which missed the analyst consensus estimate of $68.90 million by 97.39 percent.

byBill Haddad

March 16, 2022

1 minute read

BRC (NYSE:BRCC) reported quarterly sales of $1.80 million which missed the analyst consensus estimate of $68.90 million by 97.39 percent.

Jim Cramer Highlights The Missing Piece In PayPal CFO’s Departure

By Adam Eckert

Today, 6:03 PM

PayPal Holdings Inc (NASDAQ: PYPL) shares were trading lower Wednesday after the company announced the departure of CFO John Rainey.

PYPL

Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

By Benzinga Newsdesk

Today, 6:03 PM

–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of

EVLO

Barclays Upgrades Gap to Equal-Weight, Raises Price Target to $9

By Benzinga Newsdesk

Today, 6:03 PM

Barclays analyst Adrienne Yih upgrades Gap (NYSE:GPS) from Underweight to Equal-Weight and raises the price target from $6 to $9.

GPS

Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study

By Joana Scopel

Today, 6:03 PM

Gb Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, co-published a study that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation.

GBLX

BRC Q4 Sales $1.80M Miss $68.90M Estimate

Related Posts

Jim Cramer Highlights The Missing Piece In PayPal CFO’s Departure

Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Barclays Upgrades Gap to Equal-Weight, Raises Price Target to $9

Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study